Despite therapeutic immunosuppression, a significant proportion of transplanted patients develop donor-specific antibodies (DSA), which are currently recognized as the first cause of allograft failure. Generation of antibodies against protein antigens (including donor HLA) results from a thymus-dependent (TD) humoral response, which means that B cells need to receive a co-stimulation signal from activated follicular helper T cells (Tfh) to differentiate into plasmacells. METHODS: In this study, we test whether profiling of circulating Tfh (cTfh) could predict the ability to mount a TD humoral response in 36 renal transplanted patients and 9 healthy controls. We took advantage of the 2015 influenza vaccination campaign, which provided a normalized setting of antigenic stimulation. The number of cTfh, their polarisation profile, and ability to up-regulate i) helper molecules (CD40L and ICOS) and ii) the activation marker CD25 following in vitro stimulation in presence of patients' own plasma (with IS drugs) were measured prior vaccination. These parameters were then compared between responders and non-responders to influenza vaccine. RESULTS: While most of the characteristics of cTfh profile were similar between the two groups, we observed that responders showed a significantly higher proportion of cTfh17 that upregulated CD25 expression after in vitro stimulation. We performed a posteriori analysis of the cTfh profile of 15 transplanted patients at the time of DSA appearance and found that the proportion of cTfh17 cells that upregulated CD25 after in vitro stimulation was similar to responder to influenza vaccine. CONCLUSIONS: We concluded that the ability of the cTfh17 subset to be activated in vitro predicts TD antibody response and might be used as non-invasive biomarker to identify transplanted patients at risk to develop DSA.
INTRODUCTION AND AIMS:
Despite therapeutic immunosuppression, a significant proportion of transplanted patients develop donor-specific antibodies (DSA), which are currently recognized as the first cause of allograft failure. Generation of antibodies against protein antigens (including donor HLA) results from a thymus-dependent (TD) humoral response, which means that B cells need to receive a co-stimulation signal from activated follicular helper T cells (Tfh) to differentiate into plasmacells. METHODS: In this study, we test whether profiling of circulating Tfh (cTfh) could predict the ability to mount a TD humoral response in 36 renal transplanted patients and 9 healthy controls. We took advantage of the 2015 influenza vaccination campaign, which provided a normalized setting of antigenic stimulation. The number of cTfh, their polarisation profile, and ability to up-regulate i) helper molecules (CD40L and ICOS) and ii) the activation marker CD25 following in vitro stimulation in presence of patients' own plasma (with IS drugs) were measured prior vaccination. These parameters were then compared between responders and non-responders to influenza vaccine. RESULTS: While most of the characteristics of cTfh profile were similar between the two groups, we observed that responders showed a significantly higher proportion of cTfh17 that upregulated CD25 expression after in vitro stimulation. We performed a posteriori analysis of the cTfh profile of 15 transplanted patients at the time of DSA appearance and found that the proportion of cTfh17 cells that upregulated CD25 after in vitro stimulation was similar to responder to influenza vaccine. CONCLUSIONS: We concluded that the ability of the cTfh17 subset to be activated in vitro predicts TD antibody response and might be used as non-invasive biomarker to identify transplanted patients at risk to develop DSA. 
In the last few years the study on novel biomarker useful to prevent kidney rejection has grown up. Emerging data support the study of micro-RNAs (miRNAs) as possible markers in renal field. miRNAs are short non coding RNA sequences that seems to be involved in the regulation of different biological process, and they might play roles in the kidney rejection. For this reason it would be useful to verify the presence of miRNAs in renal tissue and verify their expression also in biological fluids. In this perspective we performed a miRNA profiling analysis in protocol biopsies of pediatric transplanted patients enrolled in our center. METHODS: Total RNA, containing miRNA fraction, were extracted with a commercial kit, from kidney tissue of 30 patients at one year post transplantation. All samples were previously stored at -80 C in RNAlater. miRNAs quality and concentration were evaluated by Agilent Bioanalyzer 2100 and Qubit Fluorometer. Only samples with a good RIN (Rate Integrity Number) were selected: 10 patients' samples with a normal histology (Banff I) and 10 patients' samples with acute/chronic Kidney rejection (Banff II-III-IV) were finally processed. We adopted a miRNA enrichment kit for miRNA-seq with illumina platform that suceed to analyzed a wide range of small RNA species and generate a sequencing libraries from as little as 1 ng of input material. RESULTS: miRNAs extracted from tissues show a range of concentration between 6.42 to 30.8 ng/ul with an adequate RIN of about 6.5 to 8.5. The miRNA-seq analysis showed about 1092 different miRNAs. Statistical analysis showed a significant over-expression of five miRNAs in patients with an acute or chronic rejection: hsa-miR-142-5p, hsamiR-142-3p, hsa-miR-106b-3p, hsa-miR-101-3p, hsa-miR-185-5p. CONCLUSIONS: These preliminary results showed an overexpression of 5 miRNAs in biopsies of pediatric patients with a subclinical kidney rejection. Particularly we observed that hsa-miR-142-5p and hsa-miR-142-3p have been reported as associated to acute kidney rejection in transplanted adults while hsa-miR-106b-3p, hsa-miR-101-3p, hsa-miR-185-5p have never been reported before. In order to ameliorate the monitoring and prolong the graft survival of kidney transplanted recipients, a prospective study will be performed to further correlate these data with those that will be obtained from biological fluids.
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